National Lymphangioleiomyomatosis Registry, France

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-31

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RE-LAM-CE is a registry of lymphangioleiomyomatosis cases in France. its aim is to determine the incidence and prevalence of lymphangioleiomyomatosis in France, including demographic information and information concerning the timing and modalities of diagnosis.

Based on the registry, we will set up a prospective cohort of patients. The database will include detailed medical information, particularly regarding progression of the respiratory function.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lymphangioleiomyomatosis (LAM) Registry

NCT00005486

Lung Diseases Lymphangiomyomatosis

COMPLETED

Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)

NCT00001869

Leiomyomatosis

COMPLETED

Institut Paoli Calmettes Lymphoma Database

NCT02869542

Lymphoma

RECRUITING

Living Conditions After Non-Hodgkin's Lymphoma in France

NCT05583318

Non-hodgkin's Lymphoma

COMPLETED

BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.

NCT06424379

Non Hodgkin Lymphoma Follicular Lymphoma Marginal Zone Lymphoma +1 more

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lymphangioleiomyomatosis is a rare pulmonary disease occuring preferentially in women. Few data are available regarding the epidemiology of this disease, the frequency of the various forms with mild to moderate or severe disease, and the rapid or slow progression.

Several sources of information will be used in order to increase completeness. The registry will also allow to estimate the proportion of patients with lymphangioleiomyomatosis who are managed by the Reference Center and Competence Centers for rare lung diseases in France.

Data will be collected by a research assistant, and the study will be coordinated by the Pole IMER - Department of Public health and Epidemiology of HCL (Lyon Hospitals).

This study will provide a better knowledge on the natural course of the disease and the variability in severity and progression of lymphangioleiomyomatosis, and the applicability of diagnostic criteria proposed in 2009. This study will provide the first detailed epidemiological information on Lymphangioleiomyomatosis, will assess the management of this rare disease within the French National Plan for rare diseases 2005 - 2009, and will provide valuable medical information prior to the establishment of clinical trials

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphangioleiomyomatosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with sporadic lymphangioleiomyomatosis or associated with Tuberous sclerosis.
* patients diagnosed or hospitalized or seen in consultation since 01/01/2008